Expanded access protocol with abiraterone acetate for metastatic castration-resistant prostate cancer post-chemoterapy - results in Czech Republic
Abstract
The objective of this study was to collect additional safety data in the Expanded Access Protocol with abiraterone acetate (AA) plus prednisone among subjects with metastatic castration-resistant prostate cancer (mCRPC) who have failed 1 or 2 chemotherapy regimens, 1 of which contained docetaxel. We present results of patients who were enrolled in this protocol in the Czech Republic.